<DOC>
	<DOCNO>NCT01082250</DOCNO>
	<brief_summary>A Phase I , Bioequivalent Study 2 Formulations Lurasidone HCl</brief_summary>
	<brief_title>The Bioequivalence Of Two Different Lurasidone Formulations In Patients</brief_title>
	<detailed_description>12.5 % Drugload 3X40mg vs. 25 % Drugload 1X120mg</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>1 . Diagnosis schizophrenia , schizoaffective disorder , schizophreniform disorder per DSMIV DSMIVTR criterion , opinion investigator clinically stable past 6 month . 2 . Body mass index ( BMI ) ≥ 19.5 ≤ 37 kg/m2 . 3 . No clinically relevant abnormal laboratory value . 4 . No clinically significant finding 12lead electrocardiogram ( ECG ) : 5 . No clinically significant finding vital sign measurement . 6 . Able understand provide write consent prior initiate study procedure inform nature study . 7 . Females participate study : unable child ( e.g . postmenopausal , tubal ligation , hysterectomy ) ; OR willing remain abstinent [ engage sexual intercourse ] Day 5 final followup visit ; OR willing use effective method doublebarrier birth control ( e.g . partner use condom female use diaphragm , contraceptive sponge , spermicide , intrauterine device [ IUD ] ) Day 5 final followup visit . 8 . Males must willing remain sexually abstinent use effective method birth control ( e.g . condom ) Day 5 final followup visit . 1 . Significant disease ( ) clinically significant finding ( ) physical examination determine Investigator pose health concern patient study . 2 . Known history presence intolerance psychiatric medication ( e.g . atypical antipsychotic medication ) . 3 . History alcohol drugdependence per DSMIV criterion 6month period immediately prior study entry . 4 . Significant orthostatic hypotension ( i.e . drop systolic blood pressure 30 mmHg and/or drop diastolic blood pressure 20 mmHg standing ) . 5 . Presence history ( within last year ) medical surgical condition ( e.g . gastrointestinal disease ) might interfere absorption , metabolism , excretion orally administer lurasidone . 6 . A history epilepsy risk seizure . 7 . Positive test result within 30 day prior start study : 1 . Human immunodeficiency virus ( HIV ) . 2 . Hepatitis B surface antigen Hepatitis C antibody . 3 . Urine drug abuse test ( marijuana , amphetamine , barbiturate , cocaine , opiates , benzodiazepine methadone ) . 4 . Serum betaHCG consistent pregnancy ( female ) . 8 . Participated another clinical trial receive investigational product within 30 day prior Screening . 9 . Use inhibitor inducer CYP3A4 take within 30 day prior checkin , include limited list Appendix 19.3 . 10 . Difficulty fast consume standard meal . 11 . Females take oral transdermal hormonal contraceptive within 14 day precede period 1 dosing . OR Females use implant injected hormonal contraceptive within 6 month prior period 1 dosing . 12 . Donation loss whole blood prior drug administration , follow : 1 . ≤ 499 mL within 30 day prior dose 2 . ≥ 500 mL within 56 day prior dose . 13 . Patient prolactin concentration ≥ 100 ng/mL Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Male/Female Patient</keyword>
	<keyword>Reference/Test Formulation</keyword>
	<keyword>Schizophrenia Patients</keyword>
</DOC>